Streetbeat News

Regulatory

NVDA

Nvidia shares dropped 9% due to tariff concerns after President Trump confirmed tariffs from Canada and Mexico. The stock is now at its September pre-election price.

Portfolio Pulse from

March 03, 2025 | 9:45 pm

ANIP

ANI Pharmaceuticals has received FDA approval for a new prefilled syringe format of its Purified Cortrophin Gel, simplifying administration for patients. This development could enhance the product's marketability and accessibility.

Portfolio Pulse from

March 03, 2025 | 9:45 pm

NOMD

Nomad Foods Limited (NYSE: NOMD) has released its annual report for the fiscal year ended December 31, 2024. The report is available on the company's website and the SEC's website.

Portfolio Pulse from

March 03, 2025 | 9:45 pm

CORT

Corcept Therapeutics has announced that the FDA has filed its New Drug Application for relacorilant, a selective cortisol modulator, to treat hypercortisolism.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

AMRX

Amneal Pharmaceuticals has had its Biologics License Applications (BLAs) for two Denosumab biosimilars accepted for review by the U.S. FDA. This marks a significant step in Amneal's expansion into the biosimilars market.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

SPIR

Spire Global, Inc. announced its third quarter 2024 results and the completion of its financial restatement. The company will discuss these results in a webcast.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

NDAQ

WNW

Meiwu Technology Company Limited (NASDAQ: WNW) received a notification from Nasdaq about its stock price being below $1.00 for 30 consecutive business days, failing to meet Nasdaq's minimum bid price requirement.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

SENS

Senseonics Holdings, Inc. reported its Q4 and full-year 2024 financial results. The company received FDA approval for its Eversense 365 Continuous Glucose Monitoring system and launched it with its commercial partner, Ascensia.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

GENC

Gencor Industries, Inc. announced preliminary unaudited results due to a delay in completing its audit for the Annual Report on Form 10-K for the year-end September 30, 2024. The company filed a Form 12b-25 with the SEC for both its Annual and Quarterly Reports.

Portfolio Pulse from

March 03, 2025 | 9:30 pm

REGN

Regeneron has received a positive opinion from the CHMP for conditional marketing authorization of its drug linvoseltamab, aimed at treating adults with relapsed and refractory multiple myeloma.

Portfolio Pulse from

March 03, 2025 | 9:15 pm